Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
l�ll
Further experience with the use of 6-thioguanine in patients with Crohn s disease Ansari A; Elliott T; Fong F; Arenas-Hernandez M; Rottenberg G; Portmann B; Lucas S; Marinaki A; Sanderson JInflamm Bowel Dis 2008[Oct]; 14 (10): 1399-405BACKGROUND: 6-Thioguanine (6-TG) is efficacious in patients with Crohn's Disease (CD) failing conventional immunosuppression but there are reports of hepatotoxicity. We report our experience of the safety and efficacy of 6-TG in a series of patients with CD. METHODS: A retrospective study of patients with CD who failed thiopurines +/- methotrexate between 2001 and 2006 was performed. Indications for 6-TG were; active disease, to allow infliximab withdrawal, steroid sparing, or fistula closure. Patients underwent regular review and those treated longer than 1 year were advised to have liver magnetic resonance imaging (MRI) and liver biopsy. RESULTS: All 30 patients treated with 6-TG during the period were included. The median dose and duration of 6-TG was 40 mg daily and 21.5 months, respectively. Initial clinical response was achieved in 18/30 (60%). Eleven of 29 (38%) (1 unrelated death) remained in remission at a median 44 months follow-up. Seven of 30 (23%) discontinued 6-TG due to adverse effects; 7/30 (23%) patients developed abnormal liver function tests (LFTs) during treatment, mostly transient and mild. One patient developed a portal hypertensive syndrome resolving on cessation of 6-TG. Of 11 liver biopsies, none showed nodular regenerative hyperplasia (NRH). The median red blood cell 6-thioguanine nucleotide (6-TGN) level was 807 pmol/10(8). CONCLUSIONS: 6-TG has good clinical efficacy for third-line immunosuppression in CD but hepatotoxicity remains a concern. However, previous reports of NRH in 6-TG-treated inflammatory bowel disease patients have not been substantiated by this cohort.|Adolescent[MESH]|Adult[MESH]|Biopsy[MESH]|Child[MESH]|Crohn Disease/*drug therapy/immunology[MESH]|Dose-Response Relationship, Drug[MESH]|Female[MESH]|Follow-Up Studies[MESH]|Humans[MESH]|Hypertension, Portal/chemically induced[MESH]|Liver Function Tests[MESH]|Liver/*drug effects/pathology[MESH]|Magnetic Resonance Imaging[MESH]|Male[MESH]|Middle Aged[MESH]|Remission Induction/*methods[MESH]|Retrospective Studies[MESH]|Safety[MESH]|Thioguanine/*adverse effects/*therapeutic use[MESH]|Time Factors[MESH]|Treatment Outcome[MESH]|Young Adult[MESH] |